Shifting From Counterculture to Clinical Applications, The Problems Psychedelics Face Getting to Market
Refining Psychedelics into Medicine – An Interview with Doug Drysdale, CEO of Cybin
The Renaissance of Psychedelics Research: An Interview with the CEO of MindMed, Rob Barrow
WSJ Health Forum 2022: Psychedelics Set to Take Center Stage in Mental Wellness
Low Doses of LSD as a Potential Treatment for Anxiety in the Future?
History on Depression Therapy: the Past and the Psychedelic Future
Cure or Poison? New Ventures Go IPO Continuously As “Psychedelics” Enter the Mental Health Market
Astellas and Pfizer’s Drug Receives FDA Approval as Treatment for High-Risk Prostate Cancer Recurrence